[1] 陈跃, 霍力, 兰晓莉, 等.  68Ga-DOTA-生长抑素受体PET/CT神经内分泌肿瘤显像操作指南[J]. 中国医学影像技术, 2019, 35(9): 1281-1284.   doi: 10.13929/j.1003-3289.201905060
Chen Y, Huo L, Lan XL, et al.  Guideline of 68Ga-DOTA-conjugated somatostatin receptor PET/CT imaging in neuroendocrine neoplasms[J]. Chin J Med Imaging Technol, 2019, 35(9): 1281-1284.   doi: 10.13929/j.1003-3289.201905060
[2] Nagtegaal ID, Odze RD, Klimstra D, et al.  The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76(2): 182-188.   doi: 10.1111/his.13975
[3] 蔡文, 倪寇, 葛维挺, 等.  胃肠胰神经内分泌肿瘤诊疗进展[J]. 实用肿瘤杂志, 2023, 38(3): 222-228.   doi: 10.13267/j.cnki.syzlzz.2023.035
Cai W, Ni K, Ge WT, et al.  Progress in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasm[J]. J Pract Oncol, 2023, 38(3): 222-228.   doi: 10.13267/j.cnki.syzlzz.2023.035
[4] Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, et al.  Neuroendocrine tumor heterogeneity adds uncertainty to the world health organization 2010 classification: real-world data from the Spanish tumor registry (R-GETNE)[J]. Oncologist, 2018, 23(4): 422-432.   doi: 10.1634/theoncologist.2017-0364
[5] Wolin EM.  The expanding role of somatostatin analogs in the management of neuroendocrine tumors[J]. Gastrointest Cancer Res, 2012, 5(5): 161-168.
[6] Lamberts SWJ, Hofland LJ.  Anniversary review: octreotide, 40 years later[J]. Eur J Endocrinol, 2019, 181(5): R173-R183.   doi: 10.1530/EJE-19-0074
[7] Caplin ME, Pavel M, Ćwikła JB, et al.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J]. N Engl J Med, 2014, 371(3): 224-233.   doi: 10.1056/NEJMoa1316158
[8] Krenning EP, Kooij PP, Pauwels S, et al.  Somatostatin receptor: scintigraphy and radionuclide therapy[J]. Digestion, 1996, 57(Suppl 1): S57-61.   doi: 10.1159/000201398
[9] Otte A, Mueller-Brand J, Dellas S, et al.  Yttrium-90-labelled somatostatin-analogue for cancer treatment[J]. Lancet, 1998, 351(9100): 417-418.   doi: 10.1016/S0140-6736(05)78355-0
[10] Das S, Al-Toubah T, El-Haddad G, et al.  177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(11): 1023-1031.   doi: 10.1080/17474124.2019.1685381
[11] Löser A, Schwarzenböck SM, Heuschkel M, et al.  Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival[J]. Nucl Med Commun, 2018, 39(3): 236-246.   doi: 10.1097/MNM.0000000000000795
[12] Eisenhauer EA, Therasse P, Bogaerts J, et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.   doi: 10.1016/j.ejca.2008.10.026
[13]

美国东部肿瘤协作组. 体能状态评分ECOG评分法[J/OL]. 中华普通外科学文献(电子版), 2012, 6(6): 64[2023-03-16]. http://qikan.cqvip.com/Qikan/Article/Detail?id=44045058.

Eastern Cooperative Oncology Group. Performance status score ECOG scoring method[J/OL]. Chin Arch Gen Surg (Elect Ed), 2012, 6(6): 64[2023-03-16]. http://qikan.cqvip.com/Qikan/Article/Detail?id=44045058.
[14] Bergsma H, Konijnenberg MW, Kam BLR, et al.  Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course[J]. Eur J Nucl Med Mol Imaging, 2016, 43(3): 453-463.   doi: 10.1007/s00259-015-3193-4
[15] Bergsma H, van Lom K, Raaijmakers MHGP, et al.  Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors[J]. J Nucl Med, 2018, 59(3): 452-458.   doi: 10.2967/jnumed.117.189712
[16] Forrer F, Krenning EP, Kooij PP, et al.  Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0, Tyr3]octreotate[J]. Eur J Nucl Med Mol Imaging, 2009, 36(7): 1138-1146.   doi: 10.1007/s00259-009-1072-6
[17]

Svensson J, Hagmarker L, Magnander T, et al. Radiation exposure of the spleen during 177Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume[J/OL]. EJNMMI Phys, 2016, 3(1): 15[2023-03-16]. https://ejnmmiphys.springeropen.com/articles/10.1186/s40658-016-0153-4. DOI: 10.1186/s40658-016-0153-4.
[18] Bodei L, Cremonesi M, Grana CM, et al.  Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase Ⅰ-Ⅱ study[J]. Eur J Nucl Med Mol Imaging, 2011, 38(12): 2125-2135.   doi: 10.1007/s00259-011-1902-1
[19] Rolleman EJ, Kooij PPM, de Herder WW, et al.  Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney[J]. Eur J Nucl Med Mol Imaging, 2007, 34(11): 1854-1860.   doi: 10.1007/s00259-007-0457-7
[20] Strosberg JR, Caplin ME, Kunz PL, et al.  177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2021, 22(12): 1752-1763.   doi: 10.1016/S1470-2045(21)00572-6
[21] Zhang JJ, Wang H, Jacobson O, et al.  Safety, pharmacokinetics, and dosimetry of a long-acting radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in patients with advanced metastatic neuroendocrine tumors[J]. J Nucl Med, 2018, 59(11): 1699-1705.   doi: 10.2967/jnumed.118.209841
[22] Kobayashi N, Takano S, Ito K, et al.  Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors[J]. Ann Nucl Med, 2021, 35(12): 1332-1341.   doi: 10.1007/s12149-021-01674-9